๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› DLBCL - Diffuse Large B Cell Lymphoma
Clinical trial register · China

DLBCL - Diffuse Large B Cell Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Nanjing 4 Xiamen 4 Shanghai 3 Beijing 2 Changchun 1
Narrow the registerReset
Recruitment status
Phase
Site location
Nanjing4 Xiamen4 Shanghai3 Beijing2 Changchun1
All 12 locations
Target enrolment
to

DLBCL - Diffuse Large B Cell Lymphoma trials in China

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
NCT07812493Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
Pengpeng Xu
Phase 2
24
Shanghai
2026-09-01
Not yet open
Pirtobrutinib+Sonrotoclax๏ผˆPS) Regimen in the Treatment of B-Cell Lymphoma
NCT07744750DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL
Changzhou No.2 People's Hospital
Phase 2
40
Nanjing
2026-08-30
Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
NCT07778212DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2026-08-30
Not yet open
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
NCT07744724DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Changzhou No.2 People's Hospital
Phase 2
48
Nanjing
2026-07-31
Not yet open
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
NCT07744737DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
Changzhou No.2 People's Hospital
Phase 2
34
Nanjing
2026-07-30
Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
NCT07749365DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
The First Affiliated Hospital of Xiamen University
Phase 2
53
Xiamen
2026-07-25
Not yet open
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
NCT07677813DLBCL - Diffuse Large B Cell Lymphoma
Ou Bai, MD/PHD
Phase 2
66
Changchun
2026-06-16
Recruiting
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
NCT07548697B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2026-04-30
Not yet open
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
NCT07511114DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma
Ruijin Hospital
Phase 3
156
Shanghai
2026-03-31
Not yet open
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
NCT07472621DLBCL - Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Observational
20
Zhengzhou
2026-03-10
Recruiting
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
NCT07680933DLBCL - Diffuse Large B Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2
30
Xuzhou
2026-03-01
Not yet open
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT07231250DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody
Li Zhiming
Phase 2
40
Guangzhou
2026-01-15
Recruiting
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
NCT07255963DLBCL - Diffuse Large B Cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2
29
Suzhou
2025-11-30
Not yet open
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
NCT07034508DLBCL - Diffuse Large B Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Tianjin
2025-06-20
Not yet open
AZA Combined with R-GemOx for Elderly DLBCL Patients
NCT06778902DLBCL - Diffuse Large B Cell Lymphoma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
80
Chongqing
2025-02-01
Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
NCT06891157Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
148
Nanjing
2024-08-20
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital
Observational
20
Beijing
2024-01-01
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
NCT06158399DLBCL - Diffuse Large B Cell Lymphoma, TP53
The First Affiliated Hospital of Xiamen University
Phase 2
52
Xiamen
2023-11-22
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma
Ruijin Hospital
Observational
10,000
Shanghai
2023-10-01
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/dlbcl-diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition DLBCL - Diffuse Large B Cell Lymphoma.

How many DLBCL - Diffuse Large B Cell Lymphoma trials are recruiting in China?

11 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (DLBCL - Diffuse Large B Cell Lymphoma), 21 studies
PhaseStudiesRecruitingShare
Phase 214666.7%
Observational3214.3%
Phase 3219.5%
Not applicable114.8%
Phase EARLY_PHASE1114.8%

Most active sponsors

Lead sponsors with the most studies (DLBCL - Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xiamen University44
Changzhou No.2 People's Hospital30
Ruijin Hospital21
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University10
Henan Cancer Hospital10
Institute of Hematology & Blood Diseases Hospital, China10
Li Zhiming10
Ou Bai, MD/PHD10
Peking Union Medical College Hospital11
Pengpeng Xu10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.